BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33458400)

  • 21. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
    Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-course PET based simultaneous integrated boost for locally advanced cervical cancer.
    Arnesen MR; Rekstad BL; Stokke C; Bruheim K; Løndalen AM; Hellebust TP; Malinen E
    Radiat Oncol; 2016 Mar; 11():39. PubMed ID: 26968827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours.
    Jentsch C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Krause M; Zips D; Troost EGC; Löck S; Kotzerke J; Steinbach J; Thames H; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2016 Dec; 121(3):447-452. PubMed ID: 27544820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
    Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
    Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
    Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial.
    Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.
    Shusharina N; Cho J; Sharp GC; Choi NC
    Int J Radiat Oncol Biol Phys; 2014 May; 89(1):137-44. PubMed ID: 24725696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
    Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
    Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
    J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma.
    Fan B; Fan P; Kong L; Sun X; Zhao S; Sun X; Fu Z; Zheng J; Ma L; Wang S; Hu M; Yu J
    Oncotarget; 2017 May; 8(21):34498-34506. PubMed ID: 28404900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
    Kong FM; Ten Haken RK; Schipper M; Frey KA; Hayman J; Gross M; Ramnath N; Hassan KA; Matuszak M; Ritter T; Bi N; Wang W; Orringer M; Cease KB; Lawrence TS; Kalemkerian GP
    JAMA Oncol; 2017 Oct; 3(10):1358-1365. PubMed ID: 28570742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
    Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.